The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10126
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
City of Hope Comprehensive Cancer Center LAO
Herrera, Alex Francisco
(626) 256-4673 x 62405
Phase I – 10130
A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors and B-Cell Lymphomas with Hepatic Dysfunction
University Health Network Princess Margaret Cancer Center LAO
Renouf, Daniel John
(604) 877-6000
Phase I – 10131
A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Smyth, Lillian Mary
(646) 888-4894
Phase II – 10129
A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Yale University Cancer Center LAO
LoRusso, Patricia Mucci
(203) 785-5944
Phase II – EA2165
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
ECOG-ACRIN Cancer Research Group
Rajdev, Lakshmi
(718) 405-8404
Phase II – S1701
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
SWOG
Tsao, Anne S.
(713) 792-6363
Phase II – S1712
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Yale University Cancer Center LAO
LoRusso, Patricia Mucci
(203) 785-5944
Phase II – 10129
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
SWOG
Sweet, Kendra
(813) 745-6841
Phase Other – AALL17B10-Q
DNA Methylation Stochasticity in Pediatric Acute Lymphoblastic Leukemia
Children’s Oncology Group
Koldobskiy, Michael A.
(410) 614-5055
Phase Other – AALL17B9-Q
The Genetics of Relapsed and Refractory T-Acute Lymphoblastic Leukemia (T-ALL)
Children’s Oncology Group
Ferrando, Adolfo A.
(212) 851-4611
